Comment
Author: Admin | 2025-04-28
Dogs have shown that maropitant has antiemetic effectiveness against both central and peripheral emetogens including apomorphine, and syrup of ipecac.1Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. [Review] [60 refs]. Drugs. 2000;60:533-46.EffectivenessPrevention of Acute VomitingIn laboratory model studies, maropitant citrate tablets dosed at a minimum of 2 mg/kg BW reduced the number of emetic events associated with established neural (central) and humoral (peripheral) stimuli. Following administration of apomorphine (central emetic stimuli), vomiting was observed in 33% (4 of 12) of Beagle dogs treated with maropitant citrate tablets and 100% (12 of 12) of Beagle dogs treated with placebo tablets. Following administration of syrup of ipecac (peripheral emetic stimuli) vomiting was observed in 33% (4 of 12) of Beagle dogs treated with maropitant citrate tablets and in 83% (10 of 12) of Beagle dogs treated with placebo tablets.In a study of 275 canine patients presented to veterinary hospitals with a history of acute vomiting, dogs were initially administered maropitant citrate injectable solution or placebo on Day 0. Following the initial dose, dogs allocated to the maropitant citrate group were treated with either maropitant citrate tablets at a minimum of 2 mg/kg orally or injectable solution at 1 mg/kg subcutaneously once daily at the discretion of the clinician. Dogs allocated to the placebo group were treated using either an injectable placebo solution or placebo tablets once daily at the discretion of the clinician. Of the 199 dogs included in the analysis for effectiveness, 27 of 54 dogs (50%) in the placebo group displayed vomiting at some time during the study and 31 of 145 dogs (21.4%) in the treated group displayed vomiting during the study period.Percent Of Vomiting For Each Study Day, Based Upon Treatment And Route Of Administration.DaysTreatmentRoute# dogs# vomited% vomitedDay 0Placebo (54)SC541528%maropitant citrate (145)SC145 (143*)1410%Day 1Placebo (45)PO22314%SC231670%maropitant citrate (108)PO6723%SC411639%Day 2Placebo (16)PO7229%SC9667%maropitant citrate (37)PO2400%SC13862%Day 3Placebo (6)PO200%SC4125%maropitant citrate (21)PO1400%SC7571%Day 4Placebo (2)PO100%SC11100%maropitant citrate (7)PO500%SC2150%Day 5maropitant citrate (1)SC100%*2 dogs administered maropitant citrate were not observed on Day 0. Their vomiting status was unknown. 143 was used in the denominator for % vomited.In US field studies in veterinary patients, maropitant citrate tablets and injectable solution were well tolerated in dogs presenting with various conditions including parvovirus, gastroenteritis, and renal disease. There were no notable differences in mean laboratory values between maropitant citrate-treated and placebo-treated patients.Maropitant citrate tablets were used safely in dogs receiving other frequently used veterinary products such as fluid and
Add Comment